The University Hospital Geelong is an Australian public hospital located in Ryrie Street, Geelong, Victoria. The hospital is part of Barwon Health, Victoria's largest regional health care provider, which has 21 sites.

During the past decade, Barwon Health, University Hospital Geelong conducted 46 clinical trials. In the 10-year time frame, 46 clinical trials started and 16 clinical trials were completed, i.e. on average, 34.8% percent of trials that started reached the finish line to date. In the past 5 years, 21 clinical trials started and 11 clinical trials were completed. i.e. 52.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Barwon Health, University Hospital Geelong" #1 sponsor was "Pfizer" with 6 trials, followed by "Australian and New Zealand Intensive Care Research Centre" with 5 trials sponsored, "Janssen Research & Development, LLC" with 4 trials sponsored, "Amgen" with 3 trials sponsored and "BeiGene" with 3 trials sponsored. Other sponsors include 26 different institutions and companies that sponsored additional 30 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Barwon Health, University Hospital Geelong" #1 collaborator was "National Health and Medical Research Council, Australia" with 4 trials as a collaborator, "Australian and New Zealand Intensive Care Society Clinical Trials Group" with 2 trials as a collaborator, "Australian and New Zealand Urogenital and Prostate Cancer Trials Group" with 2 trials as a collaborator, "Barwon Health" with 2 trials as a collaborator and "Breast International Group" with 2 trials as a collaborator. Other collaborators include 48 different institutions and companies that were collaborators in the rest 55 trials.

According to Clinical.Site data, the most researched conditions in "Barwon Health, University Hospital Geelong" are "Critical Illness" (2 trials), "Critically Ill" (2 trials), "Heart Failure" (2 trials), "Hypertension" (2 trials) and "Metastatic Castration Resistant Prostate Cancer" (2 trials). Many other conditions were trialed in "Barwon Health, University Hospital Geelong" in a lesser frequency.

Most popular intervention types in "Barwon Health, University Hospital Geelong" are "Drug" (39 trials), "Biological" (8 trials), "Other" (7 trials), "Procedure" (2 trials) and "Combination Product" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Azacitidine" (2 trials), "Daratumumab" (2 trials), "Dexamethasone" (2 trials) and "Empagliflozin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Barwon Health, University Hospital Geelong" are 45 trials for "All" genders, 4 trials for "Male" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Barwon Health, University Hospital Geelong". undefined are not yet recruiting, 16 are recruiting, 12 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 17 completed trials in Barwon Health, University Hospital Geelong, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Barwon Health, University Hospital Geelong, 2 "Phase 1" clinical trials were conducted, 12 "Phase 2" clinical trials and 30 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 5 trials that are defined as “Not Applicable".